Ticker

New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting

Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy

BioRestorative Therapies, Inc. (OTCMKTS:BRTX - Get Free Report) crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $0.88 and traded as low as $0.20. BioRestorative Therapies shares last traded at $0.2138, with a volume of 2,454,036 shares. BioRestorative Therapies Stock Down 6.4% The firm has

MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally…

MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase…